Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWA1211 in advanced solid tumors
NCT07363967Phase 1Recruiting
- Sponsor
- StoneWise
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SWA1211 in solid tumor (2 arms), sponsored by StoneWise. Primary endpoint: Adverse Events at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
SWA1211
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07363967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363967.